^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JBH492

    i
    Other names: JBH492
    Company:
    Novartis
    Drug class:
    Microtubule inhibitor, CCR7-targeted antibody-drug conjugate
    Related drugs:
    24d
    Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
    P1, N=25, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Business, strategic, and development considerations and not due to any safety concerns
    Trial termination
    |
    JBH492
    9ms
    Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Mar 2024 --> Sep 2024
    Trial primary completion date
    |
    JBH492
    12ms
    Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Aug 2024 --> Mar 2024
    Trial primary completion date
    |
    JBH492
    1year
    Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    JBH492
    over1year
    Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=120 --> 25 | Trial completion date: Aug 2024 --> Mar 2024 | Trial primary completion date: Aug 2024 --> Mar 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    JBH492